NewAmsterdam Pharma (NAMSW) CFO Exercises Options for 18,073 Shares
Rhea-AI Filing Summary
Louise Frederika Kooij, the reporting person and Chief Accounting Officer of NewAmsterdam Pharma Company N.V. (ticker: NAMSW), executed a transaction dated 09/02/2025 reported on Form 4. The filing shows the acquisition of 18,073 ordinary shares through the exercise of an option and reports total beneficial ownership of 33,073 ordinary shares following the transaction. The option exercised had an exercise price of EUR 1.16392, was originally granted to replace an earlier award, and included a vesting schedule described in the filing. The filing also discloses that the securities were previously held indirectly through LouFre Management B.V. for the reporting person’s benefit. The Form 4 is signed by the reporting person on 09/04/2025.
Positive
- Insider acquired 18,073 shares through option exercise, increasing direct beneficial ownership to 33,073 shares
- Exercise price disclosed (EUR 1.16392) and vesting history provided, enhancing transparency
Negative
- None.
Insights
TL;DR: Insider exercised options to acquire 18,073 shares, increasing direct beneficial ownership to 33,073 shares; transaction appears routine and non-dilutive.
The Form 4 documents an option exercise dated 09/02/2025 by the Chief Accounting Officer that resulted in acquisition of 18,073 ordinary shares at an exercise price of EUR 1.16392. The filing discloses prior indirect holding through LouFre Management B.V. and details of the option grant and vesting schedule. For investors, this is a standard insider exercise and change in beneficial ownership rather than a corporate action affecting shares outstanding or company cash flows. The reported post-transaction beneficial ownership figure (33,073 shares) provides clear context for the insider’s stake.
TL;DR: Exercise and conversion from indirect to direct ownership documented; filing provides required disclosure and vesting background.
The disclosure confirms the insider previously held the option indirectly via an entity (LouFre Management B.V.) and has exercised the option, now reflecting direct beneficial ownership. The explanatory section describes the original grant, replacement grant date and vesting mechanics, which support the legitimacy of the exercise under the issuer’s equity plan. The filing is complete in scope for a Section 16 reporting event and includes a signed certification.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option (right to buy) | 18,073 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 18,073 | $0.00 | $0.00 |
Footnotes (3)
- F1. The exercise price of the option is EUR 1.16392.
- F2. The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
- F3. The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
